144 related articles for article (PubMed ID: 341246)
1. Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
Rossi A; Bonadonna G; Valagussa P; Veronesi U
Recent Results Cancer Res; 1977; (62):134-42. PubMed ID: 341246
[No Abstract] [Full Text] [Related]
2. Adjuvant combination chemotherapy with CMF in primary mammary carcinoma.
Veronesi U; Rossi A; Bonadonna G
World J Surg; 1977 May; 1(3):337-40. PubMed ID: 883333
[No Abstract] [Full Text] [Related]
3. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
[TBL] [Abstract][Full Text] [Related]
4. The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Levitt SH; Potish RA
Cancer Clin Trials; 1981; 4(4):363-9. PubMed ID: 7032731
[TBL] [Abstract][Full Text] [Related]
5. Present status of CMF adjuvant therapy in operable breast cancer.
Bonadonna G
Int J Radiat Oncol Biol Phys; 1977; 2(3-4):237-40. PubMed ID: 324955
[No Abstract] [Full Text] [Related]
6. Multimodal treatment in operable breast cancer: five-year results of the CMF programme.
Rossi A; Bonadonna G; Valagussa P; Veronesi U
Br Med J (Clin Res Ed); 1981 May; 282(6274):1427-31. PubMed ID: 6784849
[TBL] [Abstract][Full Text] [Related]
7. Surgery and adjuvant chemotherapy in the treatment of operable breast cancer.
Rossi A; Valagussa P; Bonadonna G
Prog Clin Biol Res; 1977; 12():391-404. PubMed ID: 335401
[No Abstract] [Full Text] [Related]
8. Combination chemotherapy in disseminated carcinoma of the breast.
Stutz FH; Blom J; Tormey DC
Oncology; 1974; 29(2):139-46. PubMed ID: 4525917
[No Abstract] [Full Text] [Related]
9. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy in the primary management of breast cancer.
Fisher B
Med Clin North Am; 1977 Sep; 61(5):953-65. PubMed ID: 330977
[No Abstract] [Full Text] [Related]
11. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO
Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the toxicity of precautional chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in carcinoma of the breast in the first 700 treatment cycles].
Sismondi P; Zola P; Galletto L; De Giovanni D; Giardina G
Minerva Ginecol; 1979; 31(7-8):563-8. PubMed ID: 481814
[No Abstract] [Full Text] [Related]
13. Combination chemotherapy as an adjuvant treatment in operable breast cancer.
Bonadonna G; Brusamolino E; Valagussa P; Rossi A; Brugnatelli L; Brambilla C; De Lena M; Tancini G; Bajetta E; Musumeci R; Veronesi U
N Engl J Med; 1976 Feb; 294(8):405-10. PubMed ID: 1246307
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant chemotherapy in breast cancer: status in 1984].
Jungi WF
Wien Klin Wochenschr; 1984 Jun; 96(13):486-92. PubMed ID: 6382805
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy (CMF) for breast carcinoma: hematological side effects.
Lee YT
J Surg Oncol; 1982 Nov; 21(3):149-54. PubMed ID: 6897092
[TBL] [Abstract][Full Text] [Related]
17. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
19. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
20. Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience.
Bonadonna G; Valagussa P; Rossi A; Tancini G; Brambilla C; Marchini S; Veronesi U
Recent Results Cancer Res; 1982; 80():149-56. PubMed ID: 7036277
[No Abstract] [Full Text] [Related]
[Next] [New Search]
